Bio-Techne nelle notizie
Soluzioni proteiche e diagnostiche
Tamtam ha trovato 20 articoli recenti su Bio-Techne.
- Bio-Techne Corp. stock outperforms competitors on strong trading day
- Bio-Techne Corp. stock outperforms competitors on strong trading day
- New Bispecific Antibody Characterization Workflow Might Change The Case For Investing In Bio-Techne (TECH)
- 3 Reasons TECH is Risky and 1 Stock to Buy Instead
- Bio-Techne Corporation Trade Ideas — XETR:TE1
- Bio-Techne, Refeyn Partner on Workflow for Bispecific Antibody, Biosimilar Characterization
- Debt to equity ratio of Bio-Techne Corporation – XETR:TE1
- Why Is Techne (TECH) Up 4.5% Since Last Earnings Report?
- Bio-Techne Corp. stock outperforms competitors on strong trading day
- New 4-hour test links charge and size in bispecific antibodies and biosimilars
- Bio-Techne and Refeyn launch workflow for antibody analysis By Investing.com
- Bio-Techne (TECH) Q4 2025 Earnings Transcript
- Bio-Techne Corporation and Refeyn Announces Integrated Workflow for Bispecific Antibody and Biosimilar Characterization
- Bio-Techne and Refeyn launch integrated workflow for biologics analysis
- Assessing Bio-Techne (TECH) Valuation After Recent Share Price Rebound And Mixed Longer Term Returns
- Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization
- Bio-Techne Corp. stock underperforms Wednesday when compared to competitors despite daily gains
- How Bio-techne Corp (TECH) Affects Rotational Strategy Timing
- Bio-Techne (TECH) Q3 2026 Earnings Transcript
- Bio-Techne Corp (TECH) Stock Analysis: Exploring A Potential 18.84% Upside
Articoli raccolti da Tamtam e conservati quando riguardano l'azienda, dal più recente. Ognuno rimanda alla sua fonte.
Vendi ad aziende come Bio-Techne?
Tamtam trova le aziende in linea con il tuo cliente ideale, analizza ogni account e ti dice chi contattare e quando.
Trova aziende simili